Gaviscon from Nordic Drugs to be the first non-prescription pharmaceutical product on the market by Snabboteket AB.
The Swedish company, Snabboteket AB offers non-prescription products in smaller packs for immediate consumption using new sales channels such as trains, airports, hotels and other places where people are “on the go”. Nordic Drugs well-established product Gaviscon, for treatment of indigestion and heartburn, will be the first non-prescription pharmaceutical product included in the product portfolio of Snabboteket and will be available in a pack of two chewable tablets.
Pernilla Agardh, Marketing Manager OTC at Nordic Drugs comments:
“I see this as an excellent example of Nordic Drugs ability to adopt to new market conditions following the deregulation of the pharmacy market in Sweden some years ago. It also shows Nordic Drugs commitment to mature products in our portfolio, long-term is not just an empty phrase for us and we constantly seek to improve ourselves when it comes to life-cycle management.”
Following the successful launch of Oxycodone Lannacher, Nordic Drugs recently signed licensing agreements for two new products to be launched during 2013. We will disclose further information regarding these products at a later stage. Next chance to meet us at a partnering event will be at BIO-Europe in Barcelona 11th-13th of March, be sure to schedule
a meeting with us there if you have products of interest for the Nordic countries.
Nordic Drugs has recently launched Oxycodone controlled-release formulation as an addition to our already existing
Pain management portfolio. This launch is an example of further strengthening of the successful cooperation between Nordic Drugs and G.L. Pharma regarding generic products in the Nordic area.
From a product perspective we held a very successful European Teysuno launch event at World of GI Cancer Congress Barcelona end of June. We are all very excited
about Teysuno, our first product in the oncology portfolio,
and the possibility to offer such a high profile product to suffering patients in need.
From a business development perspective, we are about to sign agreements for at least three new products. At least one of these products will be launched already in 2012. This means that Nordic Drugs has a solid base for future growth
in coming years.
Nordic Drugs awarded Life Science company of the year 2011!
At Malmö Business Gala 2012, held February 27th, Nordic Drugs won the award Life Science company of the year 2011. Nordic Drugs was awarded the prize in competition from two other strong nominees and the motivation from the jury was as follows:
“Life Science company of the year prize is awarded a company that has had a strong positive development, looking at turnover as well as number of employees, since the start 17 years ago. Today, this company is a well-known and successful pharmaceutical company that cover all Nordic countries with its products. These products all have in common that they increase the possibility for people to live satisfactory and active lives. “
The next opportunity to meet Nordic Drugs at a partnering event will be at BIO-Europe in Amsterdam (March 19-21). Be sure to contact us if you are in Amsterdam and want to set up a meeting.
With the launch of Teysuno™ (advanced gastric cancer) Nordic Drugs will further strengthen the position as one of the leading speciality pharma companies in the Nordic region. The product will be launched early 2012 in Sweden, Denmark, Finland and Norway.
Teysuno will be the first product in the oncology portfolio currently being set up by Nordic Drugs, several potential additions to this portfolio are currently being evaluated.
During the summer 2011, Nordic Group BV and Taiho Pharmaceutical Co. entered into a development and commercialization agreement for Teysuno covering the
EU and other selected European countries.
Clinical development of Spanidin®, an immunosuppressive agent for granulomatosis with polyangiitis, GPA, (formerly known as Wegener´s) has now started in Sweden.
A total of 30 centers across Europe will be involved, six of
them are Swedish.
Anders Löfgren, Managing Director of Nordic Drugs, comments:
“Entering into clinical development with a product like Spanidin is a landmark for Nordic Drugs and further strengthens our position as a leading speciality pharma company in the Nordic region. We are proud to be part of the development of this product which will help severely sick patients. I would also like to stress the fact that 6 out of 30 involved research centers across Europe are located in Sweden.”
GPA is an incurable form of vasculitis (inflammation of blood vessels) that affects the nose, lungs, kidneys and other organs.
Nordic Drugs has been nominated in the category Life Science company of the year at Malmo Business Gala 2012. The gala will take place in February 2012 and we will of course let you know the result.
Nordic Drugs will attend BIO-Europe Milan in March. Be sure to contact us if you are in Milan and want to set up a meeting.
The Nordic Pharma Group announces a strategic collaboration with Nippon Kayaku on Spanidin® (gusperimus) in selected territories outside Japan, including Scandinavia.
Nippon Kayaku (NK) and the Nordic Pharma Group (Nordic) have signed a licensing agreement under which NK grants exclusive rights to NORDIC for the development and commercialisation of Spanidin in selected territories outside
of Japan, including Scandinavia.
Spanidin is an immunosuppressive agent developed and commercialised in Japan by NK in acute and accelerated rejection crisis after renal transplantation. The product has also obtained promising results and orphan medicinal
product status in Europe for the treatment of Wegener´s Granulomatosis (WG). Spanidin has the potential to offer a treatment for relapsing WG patients, who currently have no approved drug to cure their disease.
With this new agreement, Nordic is actively pursuing its strategy to bring innovative drugs to the market in specialized therapeutic areas that have specific, unmet medical needs. As part of Nordic Pharma Group, Nordic Drugs will take Spanidin to market in Sweden, Denmark, Finland and Norway.
During January 10-13, Nordic Drugs will attend The Finnish Medical Convention 2011 in Helsinki. Don´t hesitate to contact us at our booth if you want to learn more about our operations in Finland and/or the other Nordic countries.
Nordic Drugs has signed a distribution agreement with the Japanese pharmaceutical company Seikagaku Corporation regarding marketing of Artz®/Artzal® in Sweden, Denmark and Finland.
Artz/Artzal is a well-known product used for the treatment of pain in osteoarthritis of the knee and will be a logical addition to our Pain & Inflammation portfolio. The product was originally developed by Seikagaku Corporation and previous MA-holder in the territory was AstraZeneca.
The next opportunity to meet representatives from Nordic Drugs at a partnering event will be at BIO-Europe Munich in November.